[go: up one dir, main page]

WO2005082398A3 - Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires - Google Patents

Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires Download PDF

Info

Publication number
WO2005082398A3
WO2005082398A3 PCT/US2005/005596 US2005005596W WO2005082398A3 WO 2005082398 A3 WO2005082398 A3 WO 2005082398A3 US 2005005596 W US2005005596 W US 2005005596W WO 2005082398 A3 WO2005082398 A3 WO 2005082398A3
Authority
WO
WIPO (PCT)
Prior art keywords
type
hyperinsulinemia
diabetes
diagnosis
protection against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/005596
Other languages
English (en)
Other versions
WO2005082398A2 (fr
Inventor
John J Kopchick
Karen T Coschigano
Keith S Boyce
Andres Kriete
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio University
Cogenics Icoria Inc
Original Assignee
Ohio University
Icoria Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio University, Icoria Inc filed Critical Ohio University
Priority to CA002557181A priority Critical patent/CA2557181A1/fr
Priority to EP05713932A priority patent/EP1732582A2/fr
Priority to AU2005216922A priority patent/AU2005216922A1/en
Publication of WO2005082398A2 publication Critical patent/WO2005082398A2/fr
Publication of WO2005082398A3 publication Critical patent/WO2005082398A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'identification de gènes murins exprimés de façon différentielle dans la comparaison d'un muscle de patient normal à un muscle de patient souffrant d'hyperinsulinémie, d'un muscle de patient souffrant d'hyperinsulinémie à un muscle de patient souffrant de diabète de type 2, et d'un muscle de patient normal à un muscle de patient souffrant de diabète de type 2 par analyse à puce à ADN, ainsi que les gènes humains et protéines humaines correspondants. Les molécules humaines, ou les antagonistes de celles-ci, peuvent être utilisés dans la protection contre l'hyperinsulinémie ou le diabète de type 2, ou leurs séquelles.
PCT/US2005/005596 2004-02-26 2005-02-24 Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires Ceased WO2005082398A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002557181A CA2557181A1 (fr) 2004-02-26 2005-02-24 Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de facon differentielle dans les cellules musculaires
EP05713932A EP1732582A2 (fr) 2004-02-26 2005-02-24 Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de fa on differentielle dans les cellules musculaires
AU2005216922A AU2005216922A1 (en) 2004-02-26 2005-02-24 Diagnosis of hyperinsulinemia and type II diabetes and protection against same based on genes differentially expressed in muscle cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54751204P 2004-02-26 2004-02-26
US60/547,512 2004-02-26
US57934204P 2004-06-15 2004-06-15
US60/579,342 2004-06-15

Publications (2)

Publication Number Publication Date
WO2005082398A2 WO2005082398A2 (fr) 2005-09-09
WO2005082398A3 true WO2005082398A3 (fr) 2006-01-26

Family

ID=34915602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/005596 Ceased WO2005082398A2 (fr) 2004-02-26 2005-02-24 Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires

Country Status (4)

Country Link
EP (1) EP1732582A2 (fr)
AU (1) AU2005216922A1 (fr)
CA (1) CA2557181A1 (fr)
WO (1) WO2005082398A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1824518A4 (fr) * 2004-12-07 2009-10-28 Univ Ohio Diagnostic de l'hyperinsulinemie et du diabete de type ii et protection contre ceux-ci sur la base de proteines exprimees differemment dans le serum
GB0512401D0 (en) * 2005-06-17 2005-07-27 Randox Lab Ltd Method
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
NZ594086A (en) * 2009-02-27 2013-04-26 Verva Pharmaceuticals Ltd A drug identification protocol for type 2 diabetes based on gene expression signatures
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066787A2 (fr) * 1999-05-05 2000-11-09 Ohio University Genes et proteines hepatiques pouvant etre regules par l'hormone de croissance, utilisations associees
WO2004092419A2 (fr) * 2003-03-31 2004-10-28 Ohio University Diagnosis de l'hyperinsulinemie et du diabette de type ii et protection correspondante (i)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066787A2 (fr) * 1999-05-05 2000-11-09 Ohio University Genes et proteines hepatiques pouvant etre regules par l'hormone de croissance, utilisations associees
WO2004092419A2 (fr) * 2003-03-31 2004-10-28 Ohio University Diagnosis de l'hyperinsulinemie et du diabette de type ii et protection correspondante (i)

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"CLONTECH.PCR-Select differential screening kit. User Manual", CLONTECH, 10 September 2001 (2001-09-10), pages 1 - 35, XP002307356 *
BERNAL-MIZRACHI E ET AL: "GENE EXPRESSION PROFILING IN ISLET BIOLOGY AND DIABETES RESEARCH", DIABETES/METABOLISM RESEARCH AND REVIEWS, WILEY, LONDON,, GB, vol. 19, no. 1, 2003, pages 32 - 42, XP008045358, ISSN: 1520-7552 *
CALVO ROSA MARIA ET AL: "Immunohistochemical and morphometric studies of the fetal pancreas in diabetic pregnant rats. Effects of insulin administration", ANATOMICAL RECORD, vol. 251, no. 2, June 1998 (1998-06-01), pages 173 - 180, XP002332470, ISSN: 0003-276X *
COROMINOLA H ET AL: "Identification of novel genes differentially expressed in omental fat of obese subjects and obese type 2 diabetic patients", DIABETES, NEW YORK, NY, US, vol. 50, no. 12, December 2001 (2001-12-01), pages 2822 - 2830, XP002293068, ISSN: 0012-1797 *
GERLACH C ET AL: "PROLIFERATION-ASSOCIATED KI-67 PROTEIN IS A TARGET FOR AUTOANTIBODIES IN THE HUMAN AUTOIMMUNE DISEASE SYSTEMIC LUPUS ERYTHEMATOSUS", LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, vol. 78, no. 1, January 1998 (1998-01-01), pages 129 - 130, XP002073106, ISSN: 0023-6837 *
LIM H W ET AL: "Identification of differentially expressed mRNA during pancreas regeneration of rat by mRNA differential display", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 299, no. 5, 20 December 2002 (2002-12-20), pages 806 - 812, XP002324520, ISSN: 0006-291X *
PIETILAEINEN T ET AL: "THE IMPORTANT PROGNOSTIC VALUE OF KI-67 EXPRESSION AS DETERMINED BY IMAGE ANALYSIS IN BREAST CANCER", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 122, no. 11, 1996, pages 687 - 692, XP008028143, ISSN: 0171-5216 *
SONE H ET AL: "Pancreatic beta cell senescence contributes to the pathogenesis of type 2 diabetes in high-fat diet-induced diabetic mice.", DIABETOLOGIA. JAN 2005, vol. 48, no. 1, January 2005 (2005-01-01), pages 58 - 67, XP002332471, ISSN: 0012-186X *
SURWIT R S ET AL: "Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and AJ mice", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, vol. 44, no. 5, May 1995 (1995-05-01), pages 645 - 651, XP004540280, ISSN: 0026-0495 *

Also Published As

Publication number Publication date
CA2557181A1 (fr) 2005-09-09
EP1732582A2 (fr) 2006-12-20
WO2005082398A2 (fr) 2005-09-09
AU2005216922A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
WO2007067341A3 (fr) Compositions et procedes d’augmentation de la sensibilite a l’insuline
WO2004076639A3 (fr) Compositions et methodes destinees a diagnostiquer et traiter des maladies auto-immunes
WO2008060813A3 (fr) Anticorps antagonistes de haute affinité dirigés contre le récepteur alpha 1 de l'interleukine-13
WO2004044168A3 (fr) Rapporteurs fluorescents codes genetiquement presentant des activites de kinase, de methyltransferase et d'acetyltransferase
WO2004007675A3 (fr) Modeles d'expression du gene neuronal ou du nerf optique
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
WO2008033427A3 (fr) Compositions et procédés de détection d'une maladie lysosomale
WO2006105252A3 (fr) Diagnostic de la bronchopneumopathie chronique obstructive, et suivi de la therapie associee par analyse de l'expression de cellules sanguines
WO2005082398A3 (fr) Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires
EP2083018A3 (fr) Compositions et procédés associés à STOP-1
WO2004081043A3 (fr) Variants de baff et leurs methodes d'utilisation
EP1186672A3 (fr) Polymorphismes dans le gène humain du transporteur d'anion organique (OATP-C)
WO2003029422A3 (fr) Gene du syndrome de noonan
WO2007120156A3 (fr) Modeles animaux du syndrome du qt long congenital et leurs utilisations
WO2006063009A3 (fr) Diagnostic de l'hyperinsulinemie et du diabete de type ii et protection contre ceux-ci sur la base de proteines exprimees differemment dans le serum
WO2006122971A3 (fr) Traitement de maladies a l'aide d'un systeme d'expression regulee, ameliore
WO2005124358A3 (fr) Diagnostic et traitement de maladies associees a siglec-6
WO2005110460A3 (fr) Méthodes de traitement et diagnostics relatifs au vieillissement, particulièrement celui des muscles (14.1)
WO2005052182A3 (fr) Procede d'analyse de contenu de proteine a membrane plasmique de cellules
WO2004081535A3 (fr) Etablissement de bases de donnees de profils de structures de proteomes et utilisations desdites bases de donnees
WO2007015926A3 (fr) Systemes et procedes multiparametre de cytotoxicite a cytometrie de flux, compositions et kits d'evaluation de la susceptibilite de cellules cancereuses a une modalite de traitement
WO2006089268A8 (fr) Profils de genes et de proteines apparentees et procedes de determination de marqueurs de tissu conjonctif dans des conditions normales et pathologiques
WO2007002830A3 (fr) Diagnostic d'un hyperinsulinisme et d'un diabete de type ii et protection contre ceux-ci a partir de proteines exprimees de façon differentielle dans la peau et identifiees par proteomique
WO2006084018A3 (fr) Procede permettant de determiner la sensibilite a un traitement anticancereux
WO2004013629A3 (fr) Composes organiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2557181

Country of ref document: CA

Ref document number: 2005216922

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005216922

Country of ref document: AU

Date of ref document: 20050224

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005216922

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005713932

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005713932

Country of ref document: EP